1387.0000 -3.80 (-0.27%)
NSE Dec 19, 2025 12:33 PM
Volume: 16,417
 

1387.00
-0.27%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Number of FII/FPI investors increased from 19 to 31 in Sep 2025 qtr.
More from Tatva Chintan Pharma Chem Ltd.
Recommended